# KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

> **NCT06451757** · PHASE3 · RECRUITING · sponsor: **Khondrion BV** · enrollment: 220 (estimated)

## Conditions studied

- Mitochondrial Diseases
- Maternally Inherited Diabetes and Deafness (MIDD)
- Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
- Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

## Interventions

- **DRUG:** Sonlicromanol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06451757
- **Lead sponsor:** Khondrion BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06451757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06451757, "KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06451757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*